Crescent Biopharma, Inc.
Crescent Biopharma, Inc. (CBIO) Revenue
Annual & quarterly revenue history · segment & region breakdown
CBIO · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsCrescent Biopharma, Inc. trailing twelve-month (TTM) revenue is $0.01B, an increase of 0.00% year-over-year from $0.01B in FY2025.
Revenue trend
2025 – 2011 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.01B | +$0.01B | — |
| 2024-12-31 | $0.00B | -$0.00B | -100.00% |
| 2023-12-31 | $0.00B | -$0.00B | -86.67% |
| 2022-12-31 | $0.00B | -$0.00B | -93.53% |
| 2021-12-31 | $0.00B | -$0.01B | -88.59% |
| 2020-12-31 | $0.01B | +$0.01B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | -$0.00B | -100.00% |
| 2016-12-31 | $0.00B | -$0.02B | -99.91% |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Crescent Biopharma, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Crescent Biopharma, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Crescent Biopharma, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CBIO revenue · 4 questionsCBIO's trailing twelve-month (TTM) revenue is $0.01B. That is an increase of 0.00% year-over-year from $0.01B in FY2025.
▸ Source: FMP · Crescent Biopharma, Inc. SEC filings · GAAP · Crescent Biopharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026